NCCN 2015 Congress Series™: Melanoma
Clinicians need to be aware of the treatment and management of melanoma across the continuum of care. As the armamentarium against advanced melanoma continues to expand, clinicians need to be informed on how to select the most appropriate therapy for each patient and to carefully monitor the unique side effects. Since there is a lack of consensus on the optimal treatment for stage III disease, clinicians need to be educated on the pros and cons of each strategy. A thorough pathology report of the primary melanoma lesion at diagnosis must not be overlooked as it forms a critical basis for prognosis prediction and treatment decisions.
This educational initiative addresses health care professionals’ need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with melanoma and related skin cancers, management of both early- and late-stage diseases, and advanced cancer.
This educational program is designed to meet the educational needs of oncologists, nurses, pharmacists, dermatologists, and other health care professionals who manage patients with melanoma and related skin cancers.
Following this activity, participants should be able to:
Characteristics of a Pathology Report
- List essential tumor characteristics that should be included in the pathology report at initial melanoma diagnosis
- Outline additional pathologic factors that have prognostic or predictive value
Surgical Management of Localized Melanoma
- Describe different types of biopsy techniques for melanoma
- Summarize data on surgical margins for excising primary melanoma lesions
Systemic Therapies for Advanced Melanoma
- Compare PD-1-targeted immunotherapy with ipilimumab
- Explain the clinical data demonstrating the benefits of combining BRAF-MEK-targeted agents compared to monotherapy
Recognition and Management of Toxicities
- Identify immune-related adverse events that can occur with the use of immunotherapy and recommend appropriate monitoring and management
- Counsel patients on the toxicity profile of BRAF-targeted agents
This activity is approved for AMA PRA Category 1 Credit(s)™ for physicians and is also accredited for nurses and pharmacists. View complete accreditation details
- 3.00 Participation
- 3.00 Nurse
- 3.00 Pharmacist
- 3.00 Physician